I would also like to add that I was pleasantly surprised at the progress from 1 or 2 patients (last we heard) -- to the current ~25 patients in the Severe trial.

As we've discussed over the past week or so, if there really is a 50-patient early readout in the Severe, after 2-weeks -- then this accelerated enrollment will help for early readouts from both trials to happen in the same general time frame.

I really want CytoDyn to avoid being shoehorned into a Phase 3 Mild to Moderate trial.